![[Images/biotech-operations-intelligence-captures-trial-ops.png]]

# Biotech Operations Intelligence Captures Trial Ops—Point Solutions Become Platforms 

## Investment Take

**Consensus believes:** Biopharma ops tooling is solved. Enterprise vendors (Medidata, Veeva, IQVIA) serve large pharma, and smaller biotechs are too fragmented and short-lived to build for. Clinical trial delays are a fact of life.

**Actually:** Clinical trial operations is the last Excel stronghold in pharma. 5,950 of 6,000 pharma companies run trials on Excel spreadsheets. 50% of clinical-stage biotechs use no specialized tooling. 94% of trials are delayed >1 month, costing $600K-$8M/day. The $140B outsourcing market is "bloated and fragile"—PDFs ping-pong through inboxes, lab notes are retyped, critical insights vanish into spreadsheets.

Enterprise vendors don't serve Series A-C biotechs because their suite model requires $500K+ commitments and month-long implementations. Point solutions are capturing this gap:
- **Auxilius:** "Almost 10X revenue growth" in trial finance/accruals
- **Greenphire:** "No real competitors" in patient payments—owns the space
- **Slope:** 2.1K trials, 276 sites, 267% YoY growth in supply chain
- **Unlearn:** Digital twins promising 50% cost reduction

The data moat compounds: Auxilius's scenario modeling is "more accurate because they are more based on statistics. Their intuitive scenario model is really based on their other customers' data."

**Why now:**
- Thermo Fisher's $8.875B acquisition of Clario validates trial ops infrastructure
- China's cost arbitrage (30-50% cheaper trials, 2-3x faster enrollment) forces U.S. to automate or lose competitiveness
- FDA releases AI credibility framework for drug development
- CRO market projected $70B→$126B by 2034—automation can capture this spend

**In 5-10 years:** Point solutions that start with one wedge (supply forecasting, CDMO selection, trial accruals, patient payments) expand into integrated ops platforms. 2-3 platforms emerge as "operating systems" for biotech operations. Enterprise vendors own large pharma, platforms own Series A through mid-market.

**How this evolved:**
- *2025-12-12:* [[Jake __ Virtue]] — "5,950 companies still running clinical trials via Excel spreadsheets."
- *2025-12-21:* Source cluster emerged: Slope (supply chain), Unlearn (digital twins), Greenphire/Auxilius (payments/accruals). Shared mechanism: trial delays = massive cost, automation = clear ROI.
- *2025-12-22:* J&J says Greenphire has "no real competitors." Expert confirms 600 clinical-stage midmarket biotechs in U.S., 30-20-50 split (specialized/branded/Excel).
- *2025-12-23:* China competitive threat quantified. CRO market doubling. FDA AI framework validates automation path.
- *2025-12-29:* **MERGED** with 94% of Trials thesis—same bet, same mechanism, same winners.

---

## Mechanism

### Why Trials Fail: The Excel Problem

- **94% of trials delayed >1 month** ([[slope-seed-pitch-deck---q4-2019-05f0f0f4]])
- **$600K-$8M/day delay costs** depending on phase and therapeutic area
- **80% of trials miss enrollment timelines**, 37% of sites under-enroll ([[2025-12-23-ai-agents-are-rewriting-biopharmas-140b-playbook--]])
- **55% of clinical trials fail due to low accrual** ([[ryght-investor-presentation-25mar2025-0ecfd80c]])
- **50% of sites enroll 1 or no patients** ([[20221010-ai-in-pharma-presentation-v40-43753661]])

### Why Point Solutions Win

**Market structure:** ~600 clinical-stage biotechs in U.S. $0-500M revenue "sweet spot"—good science, cash runway, Phase II-III active.
- 50% use Excel or homegrown
- 30% use specialized tools (Auxilius, Condor, Greenphire)
- 20% use big brand enterprise

**Enterprise vendors can't serve SMB:**
- $500K+ commitments, month-long implementations
- Suite model doesn't fit 10-person virtual biotechs
- "Medidata and other big companies...keep on doing merger and acquisition activities...aware of this niche market"

**Point solution advantages:**
- 2-3 week implementations vs. months
- $50K-150K/year vs. $500K+
- Data moat: "Auxilius is more accurate because...their intuitive scenario model is really based on their other customers' data"

### China Forces Automation

- China Phase I trials cost 33% of U.S.
- Enrollment 2-3x faster (60-day "implied license" vs. FDA timelines)
- Chinese trials tripled 2017-2023 (600→2,000/year) while U.S. plateaued at 1,900
- U.S. must automate or lose competitiveness

---

## Bull Case

- [ ] **Massive underserved market.** 5,950 of 6,000 pharma companies lack systematic forecasting. 50% of clinical-stage biotechs still on Excel.
  - *Evidence:* [[Jake __ Virtue]] — "Only 50 doing forecasting... 5,950 companies still running clinical trials via Excel spreadsheets."
  - *Evidence:* [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] — "About 50% of companies... are either using homegrown Excel sheets or Microsoft AI stuff."

- [ ] **Delays are quantified and massive.** 94% of trials delayed >1 month. $600K-$8M/day cost. Over 80% of trials miss enrollment timelines, 37% of sites under-enroll.
  - *Evidence:* [[slope-seed-pitch-deck---q4-2019-05f0f0f4]] — 94% delay stat, $600K-$8M/day costs
  - *Evidence:* [[2025-12-23-ai-agents-are-rewriting-biopharmas-140b-playbook--]] — 80% miss timelines, 37% sites under-enroll

- [ ] **Data moat compounds.** Point solutions with customer data can build scenario modeling that individual companies cannot.
  - *Evidence:* [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] — "Auxilius is more accurate because... their intuitive scenario model is really based on their other customers' data."

- [ ] **M&A validates category.** Clinical data platforms command premium valuations.
  - *Evidence:* [[Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights|Thermo Fisher Clario Acquisition]] — $8.875B acquisition for clinical endpoint data infrastructure.

- [ ] **China cost arbitrage forces automation.** China Phase I trials cost 33% of U.S., enroll 2-3x faster. U.S. must automate or lose competitiveness.
  - *Evidence:* [[2025-12-23-chinas-clinical-trial-boom]] — 33% cost, 2-3x enrollment speed, tripled trials 2017-2023

- [x] **FDA embraces AI in trials.** FDA releases AI credibility framework for drug development.
  - *Evidence:* [[2025-12-23-fda-proposes-framework-to-advance-credibility-of-a]] — First FDA guidance on AI for drug/biologics development

- [ ] **Switching costs compound.** Once system of record for CDMO relationships, manufacturing schedules, supply forecasts—extremely hard to rip out.
  - *Needs validation:* Track customer retention at Auxilius (claims 50+ customers, 10X growth).

---

## Bear Case

- [ ] **Fragmented buyer with high churn.** Virtual biotechs are small, short-lived, budget-constrained. Most will "die or be consolidated"—less than 10% become bigger companies.
  - *Evidence:* [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] — "These are companies who, generally speaking, will die. Most of them will die or be consolidated."

- [ ] **Point solutions get outgrown.** Companies that survive "grow out of" Auxilius/Condor as they scale. Mid-market switches to enterprise vendors.
  - *Evidence:* [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] — "Only that 10% guys will eventually switch because they grow out of themselves."

- [ ] **Enterprise vendors move downmarket.** Medidata, Veeva, IQVIA launch "lite" versions. Brand trust + ecosystem beats point solution.
  - *Evidence:* [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] — "Medidata and other big companies, they keep on doing merger and acquisition activities... aware of this niche market right now."

- [ ] **CROs bundle operations.** If IQVIA, PPD, Parexel build native automation, standalone startups lose distribution. CRO market growing $70B→$126B (2025-2034) gives incumbents resources.
  - *Evidence:* [[2025-12-23-ai-agents-are-rewriting-biopharmas-140b-playbook--]] — CRO market doubling by 2034

- [ ] **Pharma IT buying cycles are brutal.** 9-36 month sales cycles for enterprise deals. Startups burn cash waiting.
  - *Evidence:* [[Former Vice President of Product Management at Change Healthcare _ Cohere Health _ Tegus]] — "9-36 month buying cycles"

**The counter-thesis:** If biotech mortality is so high that CAC payback is impossible (<3 years average customer lifetime), and enterprise vendors successfully acquire or build downmarket, point solutions become features rather than platforms. The intelligence layer gets absorbed into existing suites.

---

## Timeline

**Now → 2026:**
- Point solutions (Auxilius, Condor, Slope, Greenphire) continue 5-10X growth capturing underserved SMB/mid-market
- Watch for: First enterprise acquisition of point solution player (validates category)
- Biosecure Act creates CDMO selection urgency as companies navigate reshoring

**2027 → 2028:**
- Winning point solutions expand from single wedge to multi-product (forecasting → CDMO selection → trial logistics)
- Critical threshold: First platform to cross $100M ARR proves unit economics work despite high churn
- Enterprise vendors make major downmarket push (organic or M&A)
- AI-native tooling starts displacing statistical models for scenario planning

**2029+:**
- 2-3 platforms emerge as "operating systems" for biotech operations
- Data moats become defensible—new entrants can't match scenario modeling accuracy without comparable customer data
- Enterprise vendors own large pharma, platforms own Series A through mid-market
- Market structure: 30% enterprise (Medidata/Veeva), 50% platforms (evolved point solutions), 20% still Excel

---

## Startup Opportunities

### 1. Clinical Supply Forecasting Platform (Slope model)
- Real-time inventory tracking, reducing $600K-$8M/day delay costs
- Why this follows: 2.1K+ trials managed, 276 sites, 267% YoY growth proves demand
- Wedge: Early-phase trials (Phase I/II) where sponsors control more
- Risk: Late-phase dominated by CROs with own systems

### 2. Trial Finance Platform (Auxilius/Condor model)
- Accrual automation, investigator forecasting, scenario modeling
- Why this follows: 600 clinical-stage biotechs in sweet spot, mostly on Excel. Auxilius "10X revenue growth."
- Wedge: SMB biotechs ($0-500M) underserved by enterprise solutions
- Risk: Market fragmented, hard to build network effects

### 3. Digital Twins for Control Arms (Unlearn model)
- ML-generated synthetic control arms reducing enrollment by 50%
- Why this follows: Phase costs ($7M Phase I, $20M Phase II, $53M Phase III) make 50% reduction compelling
- Wedge: FDA acceptance of external control arms in specific indications
- Risk: Regulatory uncertainty on synthetic data acceptance

### 4. CDMO Selection Intelligence
- NLP mining FDA/EMA inspection reports + process requirement matching
- Why this follows: 301 CDMO partnerships announced in 2025. Virtual biotechs can't navigate "constellation of manufacturing partners."
- Wedge: Replace $50K-200K CDMO selection consultants
- Risk: CDMOs may build sponsor-side platforms with "free" software tied to manufacturing contracts

### 5. AI-Native Patient Recruitment
- EHR/RWD screening, predictive site selection, digital-first enrollment
- Why this follows: 80% of trials miss enrollment timelines, 37% sites under-enroll; China enrolls 2-3x faster
- Wedge: Regulatory tailwinds (Clinical Trial Abundance proposals, FDA AI framework)
- Risk: Requires EHR integrations, privacy/compliance overhead

### 6. Predictive Trial Monitoring
- AI-driven adverse event detection, real-time safety flagging, automated reporting
- Why this follows: Clinical Trial Abundance memo advocates replacing source data verification with risk-based monitoring
- Wedge: FDA signaled acceptance since 2013 but uptake slow
- Risk: Liability concerns if AI misses safety signals

---

## Open Questions

**Will one platform consolidate trial ops?**
→ OPEN: If Slope or similar expands from supply chain to payments to accruals, could become trial ops OS. If stays fragmented, smaller exits.

**How does FDA view synthetic control arms?**
→ OPEN: If FDA signals acceptance of digital twins, Unlearn model scales. If RCT required, limited to rare disease/oncology.

**Do CROs build or buy?**
→ OPEN: If IQVIA acquires trial ops startups, validates category but caps upside. If they build internally, threat to standalone players.

**Can U.S. match China's trial speed without cost arbitrage?**
→ OPEN: Policy reforms (Clinical Trial Abundance) could help but need Congressional action.

---

## Watch For

### Signals This Thesis is RIGHT:
- Auxilius or Condor raises growth round at $500M+ valuation
- Enterprise vendor (Medidata, Veeva) acquires point solution player for $200M+
- CRO/CDMO announces "free" sponsor-side platform (competitive response = validation)
- 2+ new entrants raise Series A for biotech ops tooling
- Clinical supply forecasting startup closes 5+ enterprise pilots in 12 months

### Signals This Thesis is WRONG:
- Auxilius/Condor growth stalls below $50M ARR (market too fragmented)
- Enterprise vendors successfully launch SMB-priced tiers without acquisition
- Biotech mortality >50% in 2020-2022 cohort analysis (CAC payback impossible)
- Microsoft Copilot/AI tools make Excel adequate for most forecasting needs
- CROs bundle native automation, standalone startups lose distribution

---

## Evidence

### Operations Intelligence Sources
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2026-01-02 | [[democratizing-data-how-wellsky-and-umed-are-bringing-clinical-trials-into-the-li]] | News | WellSky partners with uMed for home-based clinical trials via 10K+ providers |
| 2026-01-03 | [[Automation in Clinical Trial Statistical Programming A Structured Review of TLF Generation, Validati]] | Research | Pharmaverse reduces TLF dev 15-25%; LLMs achieve 88-93% F1 on clinical NLP |
| 2025-12-12 | [[Jake __ Virtue]] | Operator | "5,950 companies still running clinical trials via Excel spreadsheets." Only 50 of 6,000 do forecasting. |
| 2025-12-15 | [[Sources/Granola/Granola 1/Quinn Johns and Virtue]] | Operator | "Virtual biotechs (10-person teams) struggle to navigate constellation of manufacturing partners." |
| 2025-12-17 | [[Practical Considerations for Integrating AIML in Clinical Trials]] | Research | PROCOVA qualified (EMA 2020, FDA 2021). AI covariate adjustment works. |
| 2025-12-20 | [[Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights\|Thermo Fisher Clario Acquisition]] | Company | $8.875B acquisition validates clinical data infrastructure. |
| 2025-12-20 | [[Rebuild Biotech for the AI Era  Benchling]] | Research | "Most scientific organizations were stuck on-premise, in spreadsheets, and on paper." |
| 2025-12-23 | [[2025-12-23-ai-agents-are-rewriting-biopharmas-140b-playbook--]] | Research | "$140B outsourcing market." CRO market: $70B→$126B by 2034. 80% miss timelines. |
| 2025-12-27 | [[Director at a Pharmaceutical Therapeutics Company _ Greenphire _ Tegus]] | Operator | "50% use Excel, 30% specialized, 20% big brand." Auxilius "almost 10X revenue growth." |
| 2026-01-04 | [[Martin Naley and Emre Karatas]] | Operator | Resonata AI-powered clinical trial matching: 173-page prescribing info → 33 targetable subgroups in 15 minutes (vs 4 days manually) |
| 2026-01-04 | [[Joey (Robo) __ Virtue (Sean _ Emre)]] | Operator | Robo competitive intelligence for oncology: analyze 1000+ companies for probabilistic efficacy in combo therapies |
| 2026-01-04 | [[Ryght (VC) Investor Presentation]] | Operator | Digital site twins for 60k+ sites, AI harmonization engine; 95% of AI pilots failing validates need for specialized trial ops |
| 2026-01-04 | [[Joshua Walton and Emre Karatas]] | Operator | Multimodal foundation model for histopath/compound biomarkers, end-to-end PoS prediction from molecule through trial design |
| 2026-01-04 | [[Samir Jain and Emre Karatas]] | Operator | Medidata developing MyChart integration for patient enrollment, EHR to EDC capabilities, positioning Rave as friendliest EDC |
| 2026-01-04 | [[Sam __ Virtue]] | Operator | Eitri standardized semantics for key statistics in 50+ page CDMO-biotech documents, streamlining transitions |
| 2026-01-04 | [[Emre __ Reza]] | Operator | Katalyze AI for biologics manufacturing: 1.2% yield improvement on $15B drug = 100x ROI, $2M→$10M ARR target with GSK/BMS/Pfizer/Sanofi |
| 2026-01-04 | [[thatch---seed---jan-22-cf8590f2]] | Company | Patient-facing clinical trial matching at $2,500/referral; 80% trials delayed due to enrollment issues; 21st Century Cures Act enabling data portability |

### Trial Delays Sources
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-21 | [[slope-seed-pitch-deck---q4-2019-05f0f0f4]] | Company | 94% trials delayed >1 month. $600K-$8M/day delay costs. 2.1K trials, 276 sites. |
| 2025-12-21 | [[slope-series-a-pitch-deck_from_deals-a6027cad]] | Company | 267% YoY growth, $3M revenue, $2.4M TCV backlog. "Make clinical trials boring." Connects sponsors, CROs, patients, sites, labs with assets. |
| 2025-12-29 | [[20240711_inato---main-deck-8d6d03bd]] | Company | Inato: Clinical trial marketplace connecting sponsors with community sites. 5% of sites do 70% of research; 95% (community) do <30% but access 90% of patients. 74 active trials, 26 sponsors, 4,100+ sites. |
| 2025-12-29 | [[20240422---prism-investor-deck-3-2ef48ea0]] | Company | Prism: AI research document management. "15% of week spent on document search pre-Prism." Knowledge Finder with LLMs for pharma/biotech research teams. |
| 2025-12-21 | [[unlearnai_pitch-1-1-18540aa6]] | Company | Digital twins = 50% cost reduction, 50% fewer subjects. $80B annual trial spend. |
| 2025-12-21 | [[Contract Process Operations Lead, J&J Innovative Medicine at The Janssen Pharmaceutical Companies of Johnson & Johnson _ Greenphire _ Tegus]] | Operator | 2M+ patients in trials, complex multi-arm oncology, "no real competitors" for patient payments. |
| 2025-12-21 | [[Vice President of Finance at Velocity Clinical Research _ Greenphire _ Tegus]] | Operator | $0-500M biotech sweet spot. 35-40% are ideal candidates. |
| 2025-12-21 | [[More 2026 Clinical Predictions]] | Research | Site consolidation, AI integration struggles, human connection as differentiator. |

### China Competitive Threat
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-23 | [[2025-12-23-chinas-clinical-trial-boom]] | Research | China Phase I = 33% U.S. cost. Enrollment 2-3x faster. Trials tripled 2017-2023. |
| 2025-12-23 | [[2025-12-23-china-biotech-5yr-scenarios-autonomous-trials]] | LLM-Chat | **Exhaustive China analysis:** 30-50% preclinical cost advantage, 2-3x enrollment speed. 74% of U.S. biopharma uses Chinese manufacturers. "Autonomous Phase I" = AI protocol + remote monitoring—NOT human-free. Base case: partial decoupling (25-35% China share by 2030). $480B+ U.S. reshoring pledged but 4-10 years to build. First movers in autonomous trials (AI protocol design + wearable monitoring + digital biomarkers) gain competitive advantage. |
| 2025-12-23 | [[2025-12-23-how-to-stop-the-shift-of-drug-discovery-from-the-u]] | News | "1/3 of U.S. pharma new compounds coming from Chinese biotech firms." |

### Policy & Regulatory
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-17 | [[Weakened Biosecure Act poised to become law after Senate passage]] | Policy | Biosecure Act law. CDMO reshoring timeline pressure. |
| 2025-12-23 | [[2025-12-23-fda-proposes-framework-to-advance-credibility-of-a]] | Policy | FDA AI framework for drug development. 500+ AI submissions since 2016. |
| 2025-12-23 | [[2025-12-23-the-case-for-clinical-trial-abundance-ifp]] | Policy | Streamlined consent, risk-based monitoring, fair compensation proposals. |
| 2025-12-23 | [[2025-12-23-degette-bucshon-outline-next-steps-for-cures-21]] | Policy | "Cures 2.1: improving clinical trials, improving health IT." |
| 2025-12-23 | [[White House unveils nine new 'most favored nation' deals]] | Policy | 12 of 17 targeted pharmas committed to MFN. Margin pressure = efficiency urgency. |

### Company/Pitch Sources
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-28 | [[biogenesis-92bad6fe]] | Company | "40% of sites fail to enroll more than one patient." AI cuts trial duration 7.5→4 years. |
| 2025-12-28 | [[resonata-v0992-full-dc0b9dbd]] | Company | "Clinical trials failing to accrue (85% delayed)." AI-powered eligibility matching. |
| 2025-12-28 | [[ryght-investor-presentation-25mar2025-0ecfd80c]] | Company | "55% fail due to low accrual...failed trials cost up to $1.4B." 20K+ site digital twins. |
| 2025-12-28 | [[seer-investor-pitch-deck---confidential-c3ee5282]] | Company | "80% fail enrollment deadline. 55% terminated for enrollment failure." |
| 2025-12-28 | [[quiron-health---clinical-trial-ai-aug-2023---s2-1-360c5731]] | Company | "$2B+ revenue at risk per year of delay." Digital twins to eliminate human controls. |
| 2025-12-28 | [[20240711_inato---main-deck-8d6d03bd]] | Company | "5% of sites do more than 70% of research." Community sites = gateway to 90% of patients. |
| 2025-12-28 | [[h1-series-b-deck-9ac6670b]] | Company | H1 data platform: optimizing country/site/investigator selection. |
| 2025-12-28 | [[alchemi-05811b92]] | Company | "Report writing consumes 20-30% of scientist time." LLM-powered CRO/CDMO automation. |
| 2025-12-29 | [[Claude-Roche digital day 2024 presentation breakdown]] | LLM-Chat | **Roche Lab-in-the-Loop paradigm.** AI models generate hypotheses → automated high-throughput labs test → results retrain models. **54x improvement** vs expert medicinal chemists in molecule selection. SCimilarity: 23.4M cell atlas searched in 2 seconds. NVIDIA/Recursion partnerships for compute + screening scale. Flatiron $3.2B impairment = captive data strategy cautionary tale. "AI in drug discovery entering operational maturity at top-tier pharma." |
| 2025-12-29 | [[2025-12-23-dont-fall-in-love-with-your-molecule]] | Research | "Only half of FDA-approved molecules recoup R&D investments." |
| 2025-12-29 | [[2025-12-23-datavant-to-acquire-real-world-data-spec]] | News | Datavant acquiring Aetion—RWD consolidation. |
| 2025-12-29 | [[2025-12-23-claude-for-life-sciences]] | Research | Claude for Life Sciences with Benchling/PubMed connectors. |

---

## Related Theses

- [[Automation-Native Instruments Displace GUI-Era Incumbents—New Instrument Prime Emerges by 2032]]
- [[Protein Design Becomes Software—Wet Lab Costs Collapse 90% by 2030]]
- [[Clinical Outcome Data Becomes the Drug Discovery Moat—Computational Discovery Commoditizes by 2027]]

---

### Funding Validation (2025-12-29)
| Date | Source | Type | Key Signal |
|------|--------|------|------------|
| 2025-12-29 | [[top-20-healthcare-funding-rounds-of-2025]] | News | Tennr raised $101M Series C—validates biotech ops intelligence at scale. Hippocratic AI $141M+$126M for care automation. |
| 2025-12-29 | [[digital-health-ma-picks-up-driven-by-ai-and-private-equity]] | News | Innovaccer acquired 4 companies in 1 year including Story Health. $275M funding, "accelerate development through M&A." Validates platform consolidation thesis. |
| 2025-12-29 | [[q3-2025-market-overview-signals-out-of-sync-rock-health]] | Research | M&A volume up 37% (166 vs 121 in 2024). Many deals are "startups buying startups to build horizontal breadth." Validates point solution → platform trajectory. |
| 2025-12-29 | [[2025-12-29-veeva-systems-veev-q4-2025-earnings-call-transcrip]] | Earnings | Veeva: 17 of top 20 pharma on CTMS. "Clinical is roughly one-third of our opportunity, our TAM." EDC gaining momentum—validates clinical ops platform consolidation. |
| 2025-12-30 | [[Inato _ Virtue]] | Operator | Inato: 2.7x faster site activation via community sites. 5% of sites do 70% of research but 95% (community) access 90% of patients. Marketplace model validated. |
| 2025-12-30 | [[2025-12-30-state-of-pharmatech-2025]] | Research | State of Pharmatech: "AI agents rewriting $140B playbook." Point solutions reaching scale. Clinical ops automation accelerating. |
| 2025-12-30 | [[Bioqore Seed Deck]] | Company | Bioqore: 80% yield improvement in biologics manufacturing via AI process optimization. Validates ops intelligence beyond trial phase into CMC. |
| 2026-01-05 | [[precision-medicine-market]] | Research | Precision medicine market $119B→$537B 2025-2035 driving clinical trial complexity |
| 2026-01-05 | [[real-world-data--assessing-electronic-health-records-and-med-0088ee5f]] | Research | FDA RWD guidance impacts trial design and data infrastructure requirements |
| 2026-01-05 | [[healthcare-ai-and-the-art-of-the-possible-26-leaders-offer-predictions-for-2027]] | News | 2027 predictions for healthcare AI including clinical trials |
| 2026-01-05 | [[startups-that-could-shake-up-healthcare-in-2026]] | News | 2026 startup landscape including biotech ops players |
| 2026-01-05 | [[2026-01-01-8-predictions-for-healthcare-2026]] | News | Healthcare 2026 predictions including clinical trial innovation |

---

*Last rebuilt: 2025-12-29*
*Merged from: Biotech Operations Intelligence Captures $140B Outsourcing Market + 94% of Trials Delayed at $8M/Day—Operations Automation Wins*
*Source validation: Key operator source re-read 2025-12-29 — 600 clinical-stage biotechs, 30/20/50 market split, Auxilius 10X growth, data moat all confirmed*
*Confidence: Very High (14+ verified sources, primary operator with direct procurement experience, M&A validation)*
